Citigroup Downgrades King Pharmaceuticals (KG) to Sell
More News related to KG
- Wedbush Upgrades ZymoGenetics (ZGEN) to Outperform; Believe ZGEN on Track to Meet 2010 Sales Estimates
- King Pharmaceuticals to Present at Credit Suisse Healthcare Conference
- King Pharma (KG) Beat Q3 Views by 2c
- King Pharmaceuticals Reports Strong Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Downgrades
- JPMorgan Downgrades Tyson (TSN) to Neutral, $12 Target
- Collins Stewart downgrades Sigma Designs (SIGM) to Sell; Cisco & Motorola Using Competitor
- Wells Fargo Downgrades Prospect Capital (PSEC) to Market Perform; Credit Quality Stable But Write-Downs Could Linger
- Piper Jaffray Downgrades China Digital TV (STV) to Neutral; Long Term Opportunity Unchanged, Near-Term Visibility Low
- Canaccord Adams Downgrades Golden Star Resources Ltd. (GSS) to Hold
Citigroup downgrades King Pharmaceuticals (NYSE: KG) from Hold to Sell. Price target lowered from $21 to $16.
Citigroup analyst says, "Our thesis remains that King is likely to face declining earnings over the
medium term. Trends for the current business have been modestly stronger than expected, but declines will be driven by patent expiries yet to occur. Key products Altace and Skelaxin are likely to face generic competition before King's pipeline reaches the market, creating a sizable revenue gap. We believe King will lose operating leverage and suffer an even more pronounced earnings gap, as we see little room for cost cuts beyond reduced amortization charges."
Related Categories
DowngradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
